Frontlight ResearchEarly access
TerminatedEarly phase 1
Safety and Efficacy of NK520 to Treat Relapsed/Refractory Acute Myeloid Leukemia
Key facts
- Who runs it
- Base Therapeutics (Shanghai) Co., Ltd.
- Where
- China1 site in 1 countryChoose a country to see its sites
- Trial code
- Status
- Terminated
- Phase
- Early phase 1
- People taking part
- 2 people enrolled
- Started
- 1 Jul 2024
- Ended
- 1 Jun 2025
- Type of study
- Interventional, 3 groups
- Treatments tested
- NK520
- Record updated
- 30 September 2026
- Why it stopped
- poor accrual
Who can take part
- Age
- 18 years to 75 years
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 15 criteriaShow less
Who can take part
- Participants must be between 18 and 75 years
- Diagnostic Criteria:; Meet the 2016 World Health Organization (WHO) diagnostic criteria for acute myelocytic leukemia (AML), unsuitable for current treatments or patients with relapsed/refractory AML after ≥2 lines of therapy. The definition of relapsed/refractory acute myeloid leukemia is based on the 2017 Chinese Guidelines for Diagnosis and Treatment:; Relapsed AML: Diagnosis is confirmed when leukemia cells reappear in the peripheral blood or bone marrow blast cells exceed 5% after complete remission (CR) (excluding reasons such as bone marrow regeneration post-consolidation chemotherapy) or there is extramedullary infiltration by leukemia cells; Refractory AML: Initial cases unresponsive after two cycles of standard regimen treatment; recurrence within 12 months after CR and consolidation therapy; recurrence beyond 12 months with ineffectiveness of conventional chemotherapy; those who have relapsed twice or more; or persistent extramedullary leukemia
- Eastern Cooperative Oncology Group (ECOG) performance status score of 0 to 2
- Expected survival of at least 12 weeks
- Normal Organ Function
Who cannot take part
- Severe bleeding tendency or coagulation disorders, or currently receiving thrombolytic therapy
- Active tuberculosis (TB), currently undergoing anti-TB treatment, or treated for TB within 1 year prior to the study
- Use of immunosuppressive drugs within 1 week before the first dose, excluding topical, inhaled, or other locally administered glucocorticoids, or physiologic doses of systemic glucocorticoids (not exceeding 10 mg/day prednisone equivalent) for allergic reactions or for managing respiratory distress from asthma, chronic obstructive pulmonary disease (COPD), etc
- Receipt of live attenuated vaccines within 2 weeks before the first dose or planned during the study
- Participation in another clinical trial and receipt of investigational drug within 4 weeks prior to the first dose
- Receipt of immune-modulating drugs (including thymosin, interferons, except for local use to control pleural or ascitic fluid) within 2 weeks prior to the first dose
- Human immunodeficiency virus (HIV)-infected individuals, or known active syphilis infection
- Any other condition or situation in which the investigator deems the patient unsuitable for participation in this study
- At screening, hepatitis B or C viral tests positive according to either:; Hepatitis B surface antigen (HBsAg) positive with serum hepatitis B virus- deoxyribonucleic acid (HBV-DNA) titer ≥1×10\^3 copies/mL or above normal limits; Hepatitis C virus (HCV) antibody positive
- Acute promyelocytic leukemia
This trial has no sites in United States.
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
This study will evaluate the safety and efficacy of NK520 in the treatment of relapsed/refractory acute myeloid leukemia. NK520 will be administered by intravenous injection. The safety and efficacy of this treatment will be evaluated.
The 3 groups in the trial
- Group A(low-dose group)Treatment being tested
NK520: 3×10\^7NK/kg
Treatment: NK520
- Group B(medium-dose group)Treatment being tested
NK520: 6×10\^7NK/kg
Treatment: NK520
- Group C(high-dose group)Treatment being tested
NK520: 9×10\^7NK/kg
Treatment: NK520
Saves a reminder to your own calendar to look at this page again. Frontlight sends no messages and does not know you set it.
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- An Open, Single Center Exploratory Study to Evaluate Safety and Efficacy of NK520 for Patients With Relapsed/Refractory Acute Myeloid Leukemia
- Record updated
- 30 September 2026